NASDAQ:IRWD Ironwood Pharmaceuticals Q3 2025 Earnings Results & Report $4.68 -0.10 (-2.11%) As of 02:58 PM Eastern This is a fair market value price provided by Massive. Learn more. Ironwood Pharmaceuticals beat analyst expectations on both earnings and revenue in its Q3 2025 results, released November 10, 2025. The company reported EPS of $0.24 versus the $0.09 consensus estimate, while revenue of $122.06 million topped the $74.22 million estimate by $47.84 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 10, 2025TimeBefore Market OpensConference Call7:00 AM ET Ironwood Pharmaceuticals EPS ResultsActual EPS$0.24Consensus EPS $0.09Beat/MissBeat by +$0.15One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersIronwood Pharmaceuticals Revenue ResultsActual Revenue$122.06 millionExpected Revenue$74.22 millionBeat/MissBeat by +$47.84 millionYoY Revenue GrowthN/AConference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Ironwood Pharmaceuticals Q3 2025 Earnings FAQ Did Ironwood Pharmaceuticals beat earnings estimates for Q3 2025? Ironwood Pharmaceuticals (NASDAQ:IRWD) reported earnings of $0.24 per share for Q3 2025, beating the consensus estimate of $0.09. The report was announced on Monday, November 10, 2025. What was Ironwood Pharmaceuticals' revenue for Q3 2025? Ironwood Pharmaceuticals reported revenue of $122.06 million for Q3 2025, against a consensus estimate of $74.22 million. Ironwood Pharmaceuticals Earnings HeadlinesIronwood Pharmaceuticals Earnings Call Signals Strong 2026 MomentumNovember 17 at 10:14 PM | theglobeandmail.comIronwood Pharmaceuticals (NASDAQ:IRWD) Stock Lifted to Strong-Buy by Wall Street ZenNovember 15, 2026 | americanbankingnews.comA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.November 19 at 1:00 AM | Concord Gold Capital (Ad)Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2026 Earnings Call TranscriptNovember 6, 2026 | seekingalpha.comIronwood Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call PresentationNovember 6, 2026 | seekingalpha.comIronwood (IRWD) Q3 2026 Earnings Call TranscriptNovember 5, 2026 | finance.yahoo.comSee More Ironwood Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ironwood Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ironwood Pharmaceuticals and other key companies, straight to your email. Email Address About Ironwood PharmaceuticalsIronwood Pharmaceuticals (NASDAQ:IRWD) is a biotechnology company focused on developing and commercializing treatments for gastrointestinal diseases. Founded in 1998, the company is headquartered in Boston, Massachusetts. Its principal product is LINZESS (linaclotide), a prescription medicine for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. Ironwood and AbbVie collaborate on the product’s U.S. commercialization, while licensing partners make linaclotide available in other markets under regional brand names. Ironwood has also expanded its research and development efforts in gastrointestinal and rare diseases. Its pipeline includes apraglutide, an investigational treatment for short bowel syndrome with intestinal failure, which it obtained through its acquisition of VectivBio.View Ironwood Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItLowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027Target Stock Is Up Over 70%—Has the Easy Money Already Been Made? Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.